Barclays PLC Grows Stake in XBiotech Inc. (NASDAQ:XBIT)

Barclays PLC grew its position in XBiotech Inc. (NASDAQ:XBIT) by 247.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,343 shares of the biopharmaceutical company’s stock after purchasing an additional 18,761 shares during the quarter. Barclays PLC’s holdings in XBiotech were worth $204,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in XBiotech by 2.2% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,770 shares of the biopharmaceutical company’s stock worth $1,962,000 after purchasing an additional 5,500 shares during the last quarter. State Street Corp grew its holdings in XBiotech by 10.7% in the third quarter. State Street Corp now owns 224,595 shares of the biopharmaceutical company’s stock worth $1,736,000 after purchasing an additional 21,752 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in XBiotech by 102.9% in the second quarter. Bank of New York Mellon Corp now owns 98,314 shares of the biopharmaceutical company’s stock worth $505,000 after purchasing an additional 49,863 shares during the last quarter. American Century Companies Inc. acquired a new stake in shares of XBiotech during the second quarter worth $393,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of XBiotech by 7.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 58,437 shares of the biopharmaceutical company’s stock worth $452,000 after buying an additional 4,298 shares during the period. 55.70% of the stock is owned by hedge funds and other institutional investors.

XBiotech Trading Up 1.4 %

NASDAQ:XBIT opened at $4.48 on Tuesday. XBiotech Inc. has a 12 month low of $3.51 and a 12 month high of $9.96. The firm has a fifty day simple moving average of $6.36 and a 200-day simple moving average of $6.53. The company has a market capitalization of $136.56 million, a P/E ratio of -4.15 and a beta of 1.44.

XBiotech Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.